Introduction

Philadelphia chromosome is an abnormality resulted from 9;22 translocation. Consequently ABL proto-oncogene on chromosome 9 is fused with BCR gene on chromosome 22. This fusion produces BCR-ABL protein, mostly 210kDa (b2a2 or b3a2) or 190kDa (e1a2), with constitutively active tyrosine kinase activity promoting cell proliferation and inhibition of apoptosis. The fusion gene transcript is detectable in about 95% of CML patients and some cases of ALL. Also, serial monitoring of patients for identifying and measuring BCR-ABL transcripts provides more precise assessment of response to specific therapies and prediction of those in higher risk of disease progression.

MBCR 190 RQ provides a ready-to-use system for detection and quantitation of BCR-ABL transcripts (p190, e1a2 break point only) as well as calculation of BCR-ABL%.

This kit is based on Real-Time PCR technology. In this method application of fluorescent probes allows detection of amplified product. Analysis of fluorescent kinetics also leads to detection of the target sequence in the reaction without requiring post- amplification analysis, reducing the possibility of contamination with the PCR product. This kit is designed to be used with Rotor- Gene or StepOne machines.